title: Association of copper transporter expression with platinum resistance in epithelial ovarian cancer.
abstract: BACKGROUND
  Copper transporters (CTR) also regulate the cellular transport of platinum drugs, but their role in platinum resistance of ovarian cancer has not been elucidated.
  
  
  METHODS
  CTR expression in ovarian cancer tissues resected from patients treated by platinum-based chemotherapy was evaluated immunohistochemically. CTR2 expression in ovarian cancer cells was inhibited by bathocuproine disulfonate, and the changes in cisplatin sensitivity were examined.
  
  
  RESULTS
  CTR2 expression was increased in chemoresistant patients, but not significantly. However, the CTR2/CTR1 ratio was significantly increased in chemoresistant patients. Cases with positive CTR2 expression or positive CTR2/CTR1 ratio had poor prognoses. When the CTR2 expression in ovarian cancer cells was suppressed, sensitivity to cisplatin was significantly increased.
  
  
  CONCLUSIONS
  These data suggest that CTR2 contributes to platinum resistance in ovarian cancer. The CTR2/CTR1 ratio is a useful marker for platinum sensitivity and a potential prognostic factor in patients with ovarian cancer.
authors.affiliation: Department of Obstetrics and Gynecology, Osaka City University Graduate School of Medicine, Abeno, Osaka, Japan. hirogynecol@aol.com
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Yoshida
authors.forename: Masatomo
authors.initials: M
authors.lastname: Teramae
authors.forename: Makoto
authors.initials: M
authors.lastname: Yamauchi
authors.forename: Takeshi
authors.initials: T
authors.lastname: Fukuda
authors.forename: Tomoyo
authors.initials: T
authors.lastname: Yasui
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Sumi
authors.forename: Ken-Ichi
authors.initials: K
authors.lastname: Honda
authors.forename: Osamu
authors.initials: O
authors.lastname: Ishiko
mesh_terms: D018262:Adenocarcinoma, Clear Cell / Q000188:drug therapy / Q000378:metabolism / Q000401:mortality; D002288:Adenocarcinoma, Mucinous / Q000188:drug therapy / Q000378:metabolism / Q000401:mortality; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000494:pharmacology*; D027682:Cation Transport Proteins / Q000378:metabolism*; D002945:Cisplatin / Q000494:pharmacology*; D000079923:Copper Transporter 1; D018284:Cystadenocarcinoma, Serous / Q000188:drug therapy / Q000378:metabolism / Q000401:mortality; D019008:Drug Resistance, Neoplasm; D016889:Endometrial Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000401:mortality; D005260:Female; D005455:Fluorescent Antibody Technique; D006801:Humans; D007124:Immunoenzyme Techniques; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000401:mortality; D011379:Prognosis; D012189:Retrospective Studies; D000080083:SLC31 Proteins; D015996:Survival Rate; D014407:Tumor Cells, Cultured
chemical_list: D000970:Antineoplastic Agents; D027682:Cation Transport Proteins; D000079923:Copper Transporter 1; D000080083:SLC31 Proteins; C490079:SLC31A1 protein, human; C524078:SLC31A2 protein, human; D002945:Cisplatin